Compare
Nephros Inc vs Sonoma Pharmaceuticals, Inc. vs Vivos Therapeutics, Inc. vs Profound Medical Corp.
| Latest fiscal year | Nephros Inc NEPH | Sonoma Pharmaceuticals, Inc. SNOA | Vivos Therapeutics, Inc. VVOS | Profound Medical Corp. PROF |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2026-03-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $18.79M | $19.53M | $17.44M | $16.10M |
| Revenue growth (YoY) | +32.7% | +36.7% | +16.0% | +50.7% |
| Gross margin | 61.9% | 38.0% | 60.4% | 70.8% |
| Operating margin | 6.1% | -12.6% | -114.1% | -256.3% |
| Net margin | 6.4% | -16.3% | -121.4% | -264.4% |
| Net income | $1.19M | -$3.17M | -$21.17M | -$42.57M |
| EPS (Diluted) | $0.11 | -$1.89 | -$2.07 | $1.41 |
| Operating cash flow | $1.60M | -$3.93M | -$15.26M | -$38.21M |
| Free cash flow | n/a | -$4.12M | -$17.60M | -$38.38M |
| Cash & equivalents | $5.40M | $2.40M | $2.03M | $59.72M |
| Total assets | $13.64M | $13.96M | $25.15M | $77.47M |
| Total liabilities | $3.44M | $10.87M | $26.70M | $11.04M |
| Shareholders' equity | $10.20M | $3.10M | -$1.49M | $66.43M |
| Return on year-end equity | 11.7% | -102.6% | n/a | -64.1% |
| Shares outstanding | 10.64M | 1.80M | 9.29M | 36.29M |
Revenue, most recent five fiscal years
| Fiscal year | Nephros Inc | Sonoma Pharmaceuticals, Inc. | Vivos Therapeutics, Inc. | Profound Medical Corp. |
|---|---|---|---|---|
| Latest | $18.79M Ended 2025-12-31 | $19.53M Ended 2026-03-31 | $17.44M Ended 2025-12-31 | $16.10M Ended 2025-12-31 |
| 1 year earlier | $14.16M Ended 2024-12-31 | $14.29M Ended 2025-03-31 | $15.03M Ended 2024-12-31 | $10.68M Ended 2024-12-31 |
| 2 years earlier | $14.24M Ended 2023-12-31 | $12.73M Ended 2024-03-31 | $13.80M Ended 2023-12-31 | $7.20M Ended 2023-12-31 |
| 3 years earlier | $9.97M Ended 2022-12-31 | $13.27M Ended 2023-03-31 | $16.02M Ended 2022-12-31 | n/a |
| 4 years earlier | $10.22M Ended 2021-12-31 | $12.63M Ended 2022-03-31 | $16.89M Ended 2021-12-31 | n/a |